TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00255125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
Study: NCT01837108
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
Study: NCT01837108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004771
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00672646
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95mg, oral solution, single dose
Study: NCT00672646
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg, capsule, single dose
Study: NCT00672646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1386 Placebo oral solution
Study: NCT01544881
Drug: Technosphere Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder using the Gen2C inhaler
Study: NCT01544881
Drug: Rapid Acting Analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT03985670
Drug: teripalimab plus chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
Study: NCT03985670
Drug: chemotherapy plus teripalimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
Study: NCT00223574
Drug: Control - high carbohydrate, high glycemic index foods
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00223574
Drug: high carbohydrate, low glycemic index foods
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00223574
Drug: low carbohydrate, high monounsaturate fat foods
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01527669
Drug: LipoCol Forte capsules
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Study: NCT01527669
Drug: Lovastatin Tablet
Normalized name: Lovastatin Tablets
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Study: NCT00104234
Drug: N-acetylgalactosamine 4-sulfatase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00104234
Drug: Placebo/rhASB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00703534
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
Study: NCT00703534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule. administered as a single dose twice daily for 4 weeks
Study: NCT00703534
Drug: Gelusil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable tablets taken as needed
Study: NCT02067793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection into the arm on Day 0
Study: NCT03025594
Drug: Chirocaine ketorolac epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
Study: NCT01539915
Drug: BCT194
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied BCT194 cream (0.5%)
Study: NCT00670150
Drug: NRX 195183 (retinoid analogue)
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
Study: NCT02257736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to apalutamide once daily orally.
Study: NCT03386448
Drug: placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will receive placebo medications
Study: NCT03678753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02527005
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tabs Azithromycin 500mg daily for 3 days
Study: NCT00649025
Drug: FlutiForm 250/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT03970122
Drug: GFB-887
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP
Study: NCT03970122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching
Study: NCT03657979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-block with placebo
Study: NCT02545153
Drug: Tisseel, Baxter (Aprotinin and Fibrinogen)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
Study: NCT01085786
Drug: 14-day sequential treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Study: NCT01085786
Drug: 14-day hybrid treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Study: NCT00490516
Drug: ACP-104
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg, tablet, BID, 6 weeks
Study: NCT00490516
Drug: ACP-104
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, tablet, BID, 6 weeks
Study: NCT00002989
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03261401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to M5717
Study: NCT00679432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00679432
Drug: Asacol® 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/day, 400 mg tablets
Study: NCT04145375
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 120mg
Study: NCT00048568
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, \>= 15 mg, weekly, 1 year
Study: NCT00048568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
Study: NCT00102635
Drug: SCH66336
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
Study: NCT00864071
Drug: Grifulvin V® 125 mg/5 mL Suspension, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
Study: NCT01052090
Drug: PHN121
Approvals — FDA: no, EMA: no, PMDA: no
Description: a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
Study: NCT00605449
Drug: GSK376501
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00033644
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04652089
Drug: Simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20mg once a day for 7 days
Study: NCT04652089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day for 7 days
Study: NCT00252356
Drug: SR58611A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00826943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily x 7 days
Study: NCT01348165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution
Study: NCT02106260
Drug: CLS003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00852436
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
Study: NCT00000588
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an initial 21 day balance study to demonstrate that a selected dose of PIH produced sufficient iron excretion, patients were begun on chronic therapy. PIH or placebo were given on days 4 to 9 and days 13 to 18 in a randomized, double-blind, cross-over design.
Study: NCT02091882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo-embedded IEM tablet.
Study: NCT04340778
Drug: vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
Study: NCT04340778
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
Study: NCT00645112
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
Study: NCT02219165
Drug: Intravenous human immunoglobulin
Normalized name: immunoglobulin A, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
Study: NCT02584647
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
Study: NCT00691314
Drug: Standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
Study: NCT02154776
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks on and 1 week off
Study: NCT00004825
Drug: recombinant human insulin-like growth factor I
Normalized name: Recombinant human insulin-like growth factor I
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877265
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02483975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
Study: NCT01144286
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, single dose
Study: NCT00442806
Drug: Injection of ADRC's
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADRC's are injected
Study: NCT01651377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
Study: NCT03801252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline
Study: NCT00332007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets once daily
Study: NCT03801252
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prophylactic antibiotic
Study: NCT02478632
Drug: Subjects do not receive study medication in this study 202094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants do not receive study medication in this study 202094.
Study: NCT02733432
Drug: CD101 Vaginal Gel (3%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
Study: NCT02733432
Drug: CD101 External gel (1%)
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 external gel (1%) applied topically twice daily over 72 hours as needed
Study: NCT02733432
Drug: CD101 Vaginal Ointment (6%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
Study: NCT02733432
Drug: CD101 External ointment (1%)
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
Study: NCT01986283
Drug: Capsule
Normalized name: CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken once
Study: NCT03097120
Drug: 0.625 mg of conjugated equine estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
Study: NCT03097120
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: two placebo tablets daily
Study: NCT03797729
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
Study: NCT02745522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755196
Drug: AN2728
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 Ointment, 5%, twice daily for 12 weeks
Study: NCT00309972
Drug: Control arm (SEQ):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
Study: NCT03229057
Drug: OCP + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
Study: NCT00309972
Drug: Experimental arm (CON):
Approvals — FDA: no, EMA: no, PMDA: no
Description: concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.
Study: NCT04277910
Drug: MT2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT2004 oral capsules
Study: NCT04277910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules
Study: NCT01604850
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
Study: NCT01604850
Drug: Placebo to match SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match SOF was administered orally once daily.
Study: NCT01604850
Drug: Placebo to match RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match RBV was administered orally twice daily.
Study: NCT03677141
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive cyclophosphamide via IV.
Study: NCT03677141
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive doxorubicin via IV.
Study: NCT02958514
Drug: Tobramycin and Dexamethasone Ophthalmic Ointment
Normalized name: Tobramycin and Dexamethasone Ophthalmic Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00019097
Drug: autologous tumor cell vaccine
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000308
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00548223
Drug: Dengzhan Shengmai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 0.18g, 2#, Bid\*1year
Study: NCT00548223
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 0.18g, 2#, Bid\*1year
Study: NCT00002579
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002579
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002579
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02460159
Drug: EZ 10 mg/Atorva 20 mg FDC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02460159
Drug: EZ 10 mg/Atorva 10 mg FDC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03821883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo qd
Study: NCT01051232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subjects will receive the placebo under fasting condition.
Study: NCT02268032
Drug: Another Androgenic Agent (VRaA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 35 mg in vaginal ring
Study: NCT04519437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneous (SC) every 4 weeks (Q4W)
Study: NCT00543309
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus on CPB, then placebo infusion
Study: NCT03006068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT03829839
Drug: Placebo nasalspray
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo nasalspray contain identical ingredients except for the active agent itself.
Study: NCT03829839
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill contain identical ingredients except for the active agent itself.
Study: NCT00841919
Drug: lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff.
Study: NCT03191188
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroid hormone supplement
Study: NCT03191188
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01480089
Drug: Atomized Intraperitoneal Saline (AIS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
Study: NCT03375593
Drug: Hydrocodone 5Mg/Acetaminophen 500Mg Tab
Normalized name: HYDROCODONE 5MG/ACETAMINOPHEN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03375593
Drug: Acetaminophen 500Mg Tab
Normalized name: ACETAMINOPHEN 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03375593
Drug: Ibuprofen 600 mg tab
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet
Study: NCT01737671
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.